Therapix is a specialty pharmaceutical company focused on synthetic cannabinoid-based therapies with attractive risk/return profiles that target large, high value, under-served markets. Founded in 2004, Israeli startup Therapix Biosciences has only been working on the development of cannabinoid molecules since August 2015. Therapix expects that the prior FDA approval of dronabinol will allow them to go to market quicker. The Company has two programs they are working on; Joint Pharma and BrainBright Pharma. The Joint Pharma program is a treatment for Tourette Syndrome and is currently preparing for Phase II clinical trials starting in Q4 2016. The BrainBright Pharma program of Therapix is targeted to the high value and underserved CNS market of mild cognitive impairment (MCI) using ultra low-dose THC. Therapix filed for an IPO last month and plans to trade on NASDAQ under the ticker TRPX. Stand 06.12.2016

WKN: A1CY7H ISIN:US88339A1043 / IL0010951403 Kürzel: TRPX (TACE:THXBY - OTC:THXBD)   in  handelbar: tbd
Gründungsjahr: 2004 Haupthandelsplatz: Tel Aviv Stock Exchange / Nasdaq  Vollzogene Namenswechsel: NasVax Ltd.   Land   Angestellte: 5

Site Logo